World
Pfizer Plans Filing as Vaccine Proves 95% Effective
- Application for U.S. emergency authorization planned by Friday
- Shot staved off severe cases and also worked in older people
This article is for subscribers only.
Pfizer Inc. said a final analysis of clinical-trial data showed its Covid-19 vaccine was 95% effective, paving the way for the company to apply this week for the first U.S. regulatory authorization for a coronavirus shot.
The U.S. drugmaker and partner BioNTech SE said their vaccine protected people of all ages and ethnicities, with no significant safety problems so far in a trial that includes almost 44,000 participants.